Entrada Therapeutics ENTR-601-45：早期外显子45跳跃研究表明肌营养不良蛋白产量增加
Entrada Therapeutics has announced positive initial results from its Exon 45 Skipping Study, ELEVATE-45-201, evaluating ENTR-601-45 in people with...
Entrada Therapeutics 在杜氏肌营养不良症外显子 44 跳跃研究中将 ENTR-601-44 的剂量提高至 18 mg/kg
Entrada Therapeutics has received clearance to test the highest dose in its Exon 44 Skipping Study for Duchenne muscular...
Sapreme Therapeutics 报告称，SPM-2551 在杜氏肌营养不良症中具有显著的临床前肌营养不良蛋白恢复作用。
Sapreme Therapeutics has announced promising preclinical results for SPM-2551, an experimental treatment for Duchenne muscular dystrophy (Duchenne) that uses...